Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mass. Medicaid Advises Against Zyprexa First Line, But No Prior Authorization

Executive Summary

Massachusetts Medicaid is advising physicians against use of Lilly's atypical antipsychotic Zyprexa (olanzapine) as first-line therapy

You may also be interested in...



Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says

The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19

Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says

The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19

Crestor Impact Review To Precede Mass. Medicaid Preferred Statin Decision

Massachusetts Medicaid will assess the market impact of AstraZeneca's Crestor (rosuvastatin) before selecting a preferred statin for the program

Related Content

UsernamePublicRestriction

Register

PS041934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel